Giá trị của sự phối hợp 3 dấu ấn ung thư CEA, CYFRA 21-1, SCC huyết tương trong chẩn đoán ung thư phổi không tế bào nhỏ tại Bệnh viện Phổi Trung ương

Abstract

This study was conducted to evaluate the value of the distribution of 3 markers (CEA, CYFRA 21-1, and SCC) in the diagnosis of non-small cell lung cancer (NSCLC): 100 inpatients with non-small cell lung cancer (patient group) and 100 healthy individuals (control group) were selected for the study at the National Lung Hospital from May 2024 to May 2025. Results: The threshold and sensitivity and specificity and AUC for CEA, CYFRA 21-1 and SCC in the diagnosis of NSCLC were 5.0; 3.3; 1.5 ng/ml, and 64.0%; 66.0%; 61.0% and 60.0%; 83.0%; 72.0%, and AUC 0.881; 0.804; 0.735, respectively. The combined use of 3 markers, showed a sensitivity of 62.2% and a specificity of 85.0% with an AUC of 0.845. The sensitivity and specificity and AUC of CEA in the diagnosis of adenocarcinoma step up were 74.4%; 85.9%; 0.888. The sensitivity and specificity and AUC of SCC, CYFRA 21-1 in the diagnosis of squamous cell carcinoma step up were 90.0; 81.0% and 100; 83.0%, with AUC 0.925. The combined use of 3 markers in diagnosing adenocarcinoma showed a sensitivity and specificity of 70.5% and 88.25%, with AUC of 0.825. The combined use of 3 markers in diagnosing squamous cell carcinoma showed a sensitivity and specificity of 85.2% and 93.8% with AUC of 0.889.